Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of cancer"
DOI: 10.1016/j.ejca.2022.01.022
Abstract: PURPOSE Panphila evaluated pyrotinib plus trastuzumab, docetaxel and carboplatin as neoadjuvant therapy for early breast cancer (BC), and investigated the predictive role of immune cell subpopulations. PATIENTS AND METHODS In this multicentre phase 2 study, patients… read more here.
Keywords: cancer; phase; neoadjuvant pyrotinib; plus trastuzumab ... See more keywords
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29090476
Abstract: Background: The overexpression of the human epidermal growth factor receptor-2 (HER2) gene is present in 20~25% of breast cancer (BC) patients, contributing to an inferior prognosis. Recent clinical trials showed that pyrotinib has promising antitumor… read more here.
Keywords: pyrotinib plus; lapatinib plus; cost; versus lapatinib ... See more keywords